Skip to content

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
United Therapeutics logo
United TherapeuticsUTHR
4.4×+2.4×
Roivant Sciences logo
Roivant SciencesROIV
4.4×+2.8×
Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×
Viatris logo
ViatrisVTRS
1.1×+0.4×

Other financials

Income statement

See full
Revenue$3.0B+7.8%
Gross profit$2.6B+7.8%
Operating income$1.1B+80.6%
Net income$1.0B+59.6%
EPS (diluted)$4.02+61.5%

Balance sheet

See full
Cash & equivalents$5.5B+17.5%
Total debt$2.0B+20.5%
Total equity$19.4B+17.4%
Total assets$26.5B+15.8%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$114.63B-8.9%
Enterprise value$111.11B-9.5%
P/E26.4×
P/S9.4×-2.0×

Profitability

See full
Gross margin86.2%+0.2pp
Operating margin38.3%
Net margin35.5%

Returns & leverage

See full
Return on equity24.2%
Debt / equity0.1×0.0×
Current ratio+0.4×

Where this comes from

Calculated from Vertex Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vertex Pharmaceuticals's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vertex Pharmaceuticals's price / book?
Vertex Pharmaceuticals (VRTX) reported price / book of 5.9× in Q1 2026.
How has Vertex Pharmaceuticals's price / book changed year-over-year?
Vertex Pharmaceuticals's price / book decreased by 22.4% year-over-year, from 7.5× to 5.9×.
What is the long-term trend for Vertex Pharmaceuticals's price / book?
Over 4 years (2021 to 2025), Vertex Pharmaceuticals's price / book has grown at a 4.5% compound annual growth rate (CAGR), from 22× to 26.2×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.